6-APB was first synthesized in 1993 by David E. Nichols as a potential non-neurotoxic alternative to MDMA. However, it did not come into popular recreational use until over a decade later, where it briefly entered the rave scene and global research chemicals market. It was sold along with other novel benzofuran entactogens under the name “Benzofury”. This happened before its sale and import were subsequently banned.
Subjective effects include anxiety suppression, disinhibition, muscle relaxation, and euphoria. 6-APB’s effects are commonly compared to those of MDA and other entactogens.
Very little data exists about the pharmacological properties, metabolism, and toxicity of 6-APB, and it has only a brief history of human usage. It has been marketed alongside research chemical entactogens like 5-MAPB and 5-APB as a legal, grey-market alternative to MDMA, and is typically commercially distributed by online research chemical vendors. It is highly advised to use harm reduction practices if using this substance.